GeoVax Highlights Gedeptin's Potential in Combination Immunotherapy for Cold Tumors

GeoVax Labs, Inc. (Nasdaq: GOVX) has highlighted the expanding strategic relevance of its Gedeptin immuno-oncology program within the evolving landscape of combination immunotherapy and checkpoint inhibitor enhancement strategies. The company believes Gedeptin's unique mechanism of localized tumor destruction combined with immune activation positions the program to overcome immune resistance in immunologically cold tumors, where checkpoint inhibitors alone often prove insufficient.

Checkpoint inhibitors targeting PD-1 and PD-L1 have transformed cancer treatment, but many solid tumors remain unresponsive due to immune-suppressive tumor microenvironments, inadequate immune-cell infiltration, and incomplete tumor antigen recognition. Oncologists are increasingly focusing on combination approaches to improve response rates and extend durability of benefit. According to David Dodd, Chairman and CEO of GeoVax, “Modern immuno-oncology is increasingly shifting toward combination strategies designed to improve the effectiveness of checkpoint inhibitors across broader patient populations. We believe Gedeptin aligns directly with this trend by functioning as a potential immune-sensitization platform.”

Key characteristics of the Gedeptin platform include a tumor-agnostic mechanism of action, a strong bystander effect that destroys neighboring tumor cells even when only a fraction are directly transduced, tumor microenvironment remodeling and immune activation, and potential checkpoint sensitization supporting combination strategies with PD-1 and PD-L1 inhibitors. The platform is also compatible with image-guided and intratumoral delivery approaches across multiple solid tumor settings.

GeoVax’s lead development focus is a planned neoadjuvant combination study in recurrent head and neck squamous cell carcinoma (HNSCC), evaluating intratumoral Gedeptin together with PD-1 targeting immunotherapy in patients eligible for curative-intent surgery. The study is expected to evaluate pathologic response, immune biomarker modulation, and early event-free survival signals. Mr. Dodd noted, “The oncology field is increasingly recognizing that durable checkpoint inhibitor responses may require direct modulation of the tumor microenvironment in addition to checkpoint blockade alone. We believe Gedeptin’s ability to induce localized tumor destruction while simultaneously promoting immune activation creates a compelling rationale for combination development.”

Beyond head and neck cancer, GeoVax believes Gedeptin may have broader applicability across solid tumors characterized by established checkpoint inhibitor treatment paradigms, incomplete response durability, immunologically suppressed tumor microenvironments, and at least one lesion amenable to intratumoral or image-guided delivery. Potential future tumor targets under evaluation include melanoma, triple-negative breast cancer, cutaneous malignancies, and additional metastatic solid tumor settings.

GeoVax is advancing development plans to evaluate Gedeptin in combination with immune checkpoint inhibitors, including pembrolizumab, with the goal of amplifying anti-tumor immune activation and broadening therapeutic applicability. As the oncology landscape evolves beyond single-agent checkpoint inhibition, the company aims to position Gedeptin as a differentiated immune-enabling platform. For more information, visit www.geovax.com.